ESTUDIO EN FASE II CON TEMOZOLOMIDA EN EL TRATAMIENTO DE PACIENTES CON TUMORES DE CELULAS GERMINALES EN RECAIDA.

Datos básicos

Protocolo:
H-P00006-01
EUDRACT:
NO PROCEDE
NCT:
Centro:
Año de incio:
Año de finalización:
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

SCHERING PLOUGH SA

Resultados del Ensayo Clínico


A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer.

Okuno, Keisuke; (...); Goel, Ajay

Letter. 10.1186/s12943-022-01699-2. 2023

  • Open Access.

An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.

Xu, Caiming; (...); Goel, Ajay

Article. 10.1158/1078-0432.CCR-24-1934. 2025


Cancer worry at higher-risk sample of hereditary cancer in Spain.

Costa-Requena G, Richart-Aznar P, Segura-Huerta Á

Article. 10.1097/CEJ.0000000000000862. 2024


CNL and aCML should be considered as single entity based on molecular profiles and outcomes.

Carreño-Tarragona G; (...); Cross, Nicholas C. P.

Article. 10.1182/bloodadvances.2022008204. 2022

  • Open Access.

Comparison of psychological distress for breast, ovarian and colorectal cancer predisposition in a Spanish sample at high risk of hereditary cancer.

Costa-Requena, Gema; (...); Segura-Huerta, Angel

Article. 10.1097/CEJ.0000000000000734. 2022


Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)

Valladares-Ayerbes, M; (...); Vila, AL

Meeting Abstract. 10.1016/j.annonc.2021.08.976. 2021

  • Open Access.

Correction: Update on the management of elderly patients with colorectal cancer.

Soler-González G; (...); Gironés-Sarrió R

Correction. 10.1007/s12094-023-03351-x. 2024

  • Open Access.

Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning.

Munoz, Andres J.; (...); Hernandez-Presa, Miguel Angel

Article. 10.1016/j.thromres.2023.06.015. 2023


Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.

Capdevila, J.; (...); Manzano, J. L.

Article. 10.1038/s41467-023-38611-5. 2023

  • Open Access.

Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

Contreras-Toledo, Debora; (...); Carmona-Bayonas, Alberto

Article. 10.1038/s41416-023-02563-w. 2024


European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance.

Boormans, Joost; (...); Laguna, Pilar

Meeting Abstract. 2023


Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study.

Valladares-Ayerbes M; (...); Lloansí Vila A

Article. 10.3390/cancers14246075. 2022

  • Open Access.

First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort

Oliveres, H.; (...); Maurel, J.

Meeting Abstract. 10.1016/j.annonc.2023.09.1796. 2023


Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Rodríguez-Lescure Á; (...); de la Haba-Rodriguez J

Article. 10.1007/s12094-024-03411-w. 2024

  • Open Access.

Initial Clinical and Treatment Patterns of Advanced Differentiated Thyroid Cancer. ERUDIT Study.

Vallejo Casas, Juan Antonio; (...); Orcajo-Rincon, Lorenzo

Article. 10.1530/ETJ-21-0111. 2022

  • Open Access.

Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

Alonso-Gordoa, T.; (...); de La Cruz, G.

Meeting Abstract. 2022


Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.

Raga, Mireia Gil; (...); Hernandez, Isabel Busquier

Article. 10.1007/s12094-022-03047-8. 2023


MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma

Baste Rotllan, N.; (...); Mesia, R.

Meeting Abstract. 10.1016/j.annonc.2023.09.999. 2023

  • Open Access.

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

del Olmo-Garcia, Maria I.; (...); Merino-Torres, Juan F.

Article. 10.3390/cancers14030584. 2022

  • Open Access.

Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.

Ortuzar, Ariana; (...); Osorio, Santiago

Article. 10.1007/s00277-022-05044-x. 2022

  • Open Access.

Precision medicine in metastatic colorectal cancer: targeting KRAS G12C mutation

Aparicio, Jorge

Article. 10.21037/tgh-24-28. 2024

  • Open Access.

Predicting major bleeding events in anticoagulated cancer patients with venous thromboembolism using real-world data and machine learning.

Martin, Andres J. Munoz; (...); Hernandez-Presa, Miguel Angel

Meeting Abstract. 2022


Predicting recurrence of venous thromboembolism in anticoagulated cancer patients using real-world data and machine learning.

Martin, Andres J. Munoz; (...); Hernandez-Presa, Miguel Angel

Meeting Abstract. 2022


Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing.

Munoz Martin, Andres J; (...); Hernandez-Presa, Miguel Angel

Article. 10.1007/s12094-024-03586-2. 2024

  • Open Access.

Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families

Fonfria, M; (...); Martinez-Duenas, E

Article. 10.3390/jpm11060548. 2021

  • Open Access.

Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.

Boormans, Joost L; (...); Laguna, M Pilar

Article. 10.1016/j.euo.2023.10.014. 2023


Psychiatric symptoms in a Spanish sample with hereditary cancer risk.

Costa-Requena G; (...); Segura-Huerta Á

Article. 10.1007/s12687-022-00580-5. 2022

  • Open Access.

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Aparicio, Jorge; (...); Maurel, Joan

Article. 10.1007/s12094-022-02868-x. 2022

  • Open Access.

Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)

Aparicio, J; (...); Maurel, J

Meeting Abstract. 10.1016/j.annonc.2021.08.937. 2021

  • Open Access.

Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study.

López Muñoz AM; (...); Martín Gómez T

Article. 10.1007/s12094-024-03630-1. 2024


Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions

Vera Garcia, R.; (...); Mondejar Solis, R.

Meeting Abstract. 10.1016/j.annonc.2023.04.343. 2023

  • Open Access.

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022).

Fernandez Montes, Ana; (...); Aparicio, Jorge

Article. 10.1007/s12094-023-03199-1. 2023

  • Open Access.

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).

Castillón JC; (...); Plazas JG

Article. 10.1007/s12094-023-03205-6. 2023

  • Open Access.

SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).

Arranz Arija, Jose Angel; (...); Gonzalez-Billalabeitia, Enrique

Article. 10.1007/s12094-024-03532-2. 2024

  • Open Access.

Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.

Valladares-Ayerbes M; (...); Lloansí Vila A

Article. 10.1007/s12094-024-03487-4. 2024

  • Open Access.

Update on the management of elderly patients with colorectal cancer.

Soler-Gonzalez, Gemma; (...); Girones-Sarrio, Regina

Article. 10.1007/s12094-023-03243-0. 2023

  • Open Access.

Venous thromboembolism recurrence during anticoagulant treatment in gastrointestinal cancer patients

Munoz Martin, A.; (...); Angel Hernandez-Presa, M.

Meeting Abstract. 2022


Campos de Estudio

Compartir